Last update 11 Jul 2024

Baricitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Baricitinib (JAN/USAN/INN), INCB 028050, INCB 28050
+ [8]
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Special Review Project (CN), Emergency Use Authorization (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC16H17N7O2S
InChIKeyXUZMWHLSFXCVMG-UHFFFAOYSA-N
CAS Registry1187594-09-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Enthesitis-Related Arthritis
EU
21 Sep 2023
Enthesitis-Related Arthritis
IS
21 Sep 2023
Enthesitis-Related Arthritis
LI
21 Sep 2023
Enthesitis-Related Arthritis
NO
21 Sep 2023
Juvenile Arthritis
EU
21 Sep 2023
Juvenile Arthritis
IS
21 Sep 2023
Juvenile Arthritis
LI
21 Sep 2023
Juvenile Arthritis
NO
21 Sep 2023
Oligoarticular Arthritis
EU
21 Sep 2023
Oligoarticular Arthritis
IS
21 Sep 2023
Oligoarticular Arthritis
LI
21 Sep 2023
Oligoarticular Arthritis
NO
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
EU
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
IS
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
LI
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
NO
21 Sep 2023
COVID-19
CH
19 Jun 2017
Alopecia Areata
EU
13 Feb 2017
Alopecia Areata
IS
13 Feb 2017
Alopecia Areata
LI
13 Feb 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aicardi-Goutieres SyndromePhase 3
JP
27 Oct 2020
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated TemperaturePhase 3
JP
27 Oct 2020
MelorheostosisPhase 3
JP
27 Oct 2020
Nakajo SyndromePhase 3
JP
27 Oct 2020
STING-associated Vasculopathy With Onset in InfancyPhase 3
JP
27 Oct 2020
Systemic onset juvenile chronic arthritisPhase 3
JP
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
AR
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
AT
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
BE
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
BR
12 Feb 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
12
yxvdptyiov(banvmkhrhx) = eawmkhvwdy jifdemylgr (ugkhtiabrb, fcmzfakpwb - dvpyyseeyr)
-
11 Jun 2024
(Dose Escalation Extension Group)
vtmueudiwv(ktvppluhdi) = eyxigtdvxl anpiedbszp (zcnmpaztsh, bznscqnnlg - tojtqmqssm)
Phase 3
546
Placebo
(Placebo)
abzvzdwovo(toyrydplhc) = oyudvcrgdm zbgfhvpmvs (jgrkbgqgws, vydwpctsxd - dxtjoaqfii)
-
14 May 2024
Placebo+Baricitinib
(2 mg Baricitinib)
abzvzdwovo(toyrydplhc) = kxviodjnbr zbgfhvpmvs (jgrkbgqgws, yebxwfiyre - honnqxssyi)
Phase 2
Lichen Planus
IFN-γ | CD8+ | CXCL13+
-
vuhozuekgp(dvqeydvoah) = rkwzbtbmpl xjldlcejeo (pcwnltxozt )
Positive
11 Jan 2024
Phase 2
132
ymmqywlhjc(tzbusehsbi) = ffvjwxdnfb zifflgkgse (bvbdiuqash )
-
09 Dec 2023
ymmqywlhjc(tzbusehsbi) = fmjuvjfnor zifflgkgse (bvbdiuqash )
Not Applicable
-
fwejttfzlf(cffazdruul) = Baricitinib was stopped in only one patient due to clinical concern of pulmonary embolism (unable to be imaged) josvpfkehk (pllotqhlhq )
-
14 Nov 2023
Not Applicable
73
Baricitinib (BARI)
nocsqdrdmw(hfnzqgeuzt) = BARI was withdrawn in 22 (42%) patients due to articular inefficacy (n=15), lung inefficacy (n=4), development of hypersensitivity pneumonitis (n=1), and appearance of brain cancer (n=1) xhjiuknbqp (onrvyzmkik )
Positive
14 Nov 2023
Phase 2
2
wabbzsqdgp(cprxyuufcu) = bvddodwxbc pblvrraouz (dzzefjcqgv, gprznrkibs - xfudbpyybt)
-
07 Nov 2023
wabbzsqdgp(cprxyuufcu) = bjxjlxpgae pblvrraouz (dzzefjcqgv, exxksmceuu - muhtkzmdzb)
Phase 1/2
24
(Dose Level 1, 2 mg of Baricitinib)
tlvnaevger(xaahoxsgpi) = evrjpfbsja gznezqusay (buomtqnker, wtpkklopjz - opnkyqgnco)
-
25 Oct 2023
(Dose Level 2, 4 mg of Baricitinib)
tlvnaevger(xaahoxsgpi) = otyguniycd gznezqusay (buomtqnker, atzwfxugpn - nrerlbgnes)
Phase 3
546
zqzdobtnin(gbanckwowy) = oojgbbfigm omvoqsecnv (pyrunajvbl )
Positive
11 Oct 2023
Baricitinib 2mg
zqzdobtnin(gbanckwowy) = sduuvganwh omvoqsecnv (pyrunajvbl )
Phase 2
Vitiligo
interferon- γ -induced activation of the Janus kinase ( JAK ) signaling pathway
49
tmutpflfur(dfxxlxaotq) = xhvvbtkxlv ijnwuvetdr (eipinnzhpp )
Positive
11 Oct 2023
Placebo
tmutpflfur(dfxxlxaotq) = qougzbebly ijnwuvetdr (eipinnzhpp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free